Sildalis: Advanced Dual-Action Therapy for Erectile Dysfunction
| Product dosage: 120mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $5.02 | $50.21 (0%) | 🛒 Add to cart |
| 20 | $3.01 | $100.41 $60.25 (40%) | 🛒 Add to cart |
| 30 | $2.68 | $150.62 $80.33 (47%) | 🛒 Add to cart |
| 60 | $1.67 | $301.24 $100.41 (67%) | 🛒 Add to cart |
| 90 | $1.56 | $451.86 $140.58 (69%) | 🛒 Add to cart |
| 120 | $1.42 | $602.47 $170.70 (72%) | 🛒 Add to cart |
| 180 | $1.23 | $903.71 $220.91 (76%) | 🛒 Add to cart |
| 270 | $1.00 | $1355.57 $271.11 (80%) | 🛒 Add to cart |
| 360 | $0.95
Best per pill | $1807.42 $341.40 (81%) | 🛒 Add to cart |
Synonyms | |||
Similar products
Sildalis represents a significant advancement in the pharmacological management of erectile dysfunction (ED), combining two well-established active compounds into a single, potent formulation. This medication is specifically engineered for men who require a more robust therapeutic approach than monotherapy can provide. By leveraging the synergistic effects of sildenafil citrate and tadalafil, Sildalis offers a unique dual-mechanism action that targets both the rapid onset and extended duration of efficacy. Its development is grounded in extensive clinical understanding of phosphodiesterase type 5 (PDE5) inhibition, making it a cornerstone option for urologists and patients seeking reliable, effective treatment. This expert overview details the pharmacological profile, appropriate usage, and essential safety information for this specialized compound.
Features
- Dual active pharmaceutical ingredients: Sildenafil Citrate (50 mg) and Tadalafil (10 mg)
- Mechanism of Action: Potent and selective inhibition of phosphodiesterase type 5 (PDE5)
- Formulation: Oral tablet for convenient administration
- Onset of Action: Typically within 30-60 minutes post-administration
- Duration of Efficacy: Provides a therapeutic window of up to 24-36 hours
- Bioavailability: Optimized for rapid absorption, with food intake potentially delaying rate of absorption
Benefits
- Dual-Mechanism Efficacy: Combines the rapid onset characteristic of sildenafil with the prolonged duration of action provided by tadalafil, offering a comprehensive therapeutic profile.
- Enhanced Spontaneity: The extended window of efficacy reduces the need for precise timing of medication in relation to sexual activity, alleviating psychological pressure and supporting a more natural intimate experience.
- Improved Rigidity: Facilitates strong and sustainable erectile responses sufficient for satisfactory sexual intercourse by significantly increasing blood flow to the corpus cavernosum.
- Proven Reliability: Formulated with two of the most extensively researched and clinically validated PDE5 inhibitors, ensuring a predictable and dependable treatment outcome.
- Streamlined Treatment Regimen: Consolidates two therapeutic effects into a single tablet, simplifying the treatment protocol and enhancing patient adherence.
Common use
Sildalis is exclusively indicated for the treatment of erectile dysfunction (ED) in adult men. Erectile dysfunction is characterized by the consistent or recurrent inability to achieve and/or maintain a penile erection sufficient for satisfactory sexual performance. The use of Sildalis is predicated on the presence of sexual stimulation; it is not an aphrodisiac and will not trigger an erection in the absence of erotic stimuli. It is prescribed for patients in whom monotherapy with a standard PDE5 inhibitor may have provided suboptimal results or for those who, under expert medical guidance, are deemed suitable candidates for its specific dual-action profile.
Dosage and direction
The standard recommended dosage of Sildalis is one tablet taken orally, approximately 30-60 minutes before anticipated sexual activity. The tablet should be swallowed whole with a full glass of water. It may be taken with or without food; however, consumption with a high-fat meal may delay the onset of action. The dosing should not exceed one tablet within a 24-hour period. The unique pharmacokinetics of the combined agents necessitate strict adherence to this once-daily maximum to mitigate the risk of adverse effects. Dosage adjustments, particularly for patients with underlying health conditions, must be determined solely by a qualified healthcare professional based on efficacy and tolerability.
Precautions
- Prior to initiation, a thorough medical evaluation is mandatory to diagnose ED, identify potential underlying causes (e.g., cardiovascular, neurological, or hormonal), and assess cardiovascular health, as sexual activity carries a potential cardiac risk.
- Use with caution in patients with anatomical deformation of the penis (e.g., angulation, cavernosal fibrosis, or Peyronie’s disease) or conditions predisposing them to priapism (e.g., sickle cell anemia, multiple myeloma, or leukemia).
- Caution is advised in patients with bleeding disorders or active peptic ulceration.
- Not recommended for use in women or children.
- Sildalis offers no protection against sexually transmitted diseases.
Contraindications
Sildalis is strictly contraindicated in the following scenarios:
- Concomitant administration with any form of organic nitrate therapy (e.g., nitroglycerin, isosorbide mononitrate or dinitrate) or nitric oxide donors. This combination can cause a severe, life-threatening drop in blood pressure.
- Hypersensitivity to sildenafil citrate, tadalafil, or any of the excipients within the formulation.
- Patients with severe hepatic impairment (Child-Pugh Class C).
- Patients with severe cardiovascular instability, including hypotension (BP < 90/50 mmHg), uncontrolled hypertension, or those who have experienced a recent myocardial infarction, stroke, or life-threatening arrhythmia.
- Patients with hereditary degenerative retinal disorders, including retinitis pigmentosa.
- Concomitant use with potent CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole) is contraindicated.
Possible side effect
As with all potent pharmacological agents, Sildalis may cause adverse reactions. The most commonly reported side effects are generally mild to moderate and transient, often related to its vasodilatory properties. These include:
- Very Common (>1/10): Headache, flushing.
- Common (1/10 to 1/100): Dyspepsia, nasal congestion, dizziness, back pain, myalgia, visual disturbances (including blurred vision, cyanopsia).
- Uncommon (1/100 to 1/1000): Palpitations, tachycardia, hypotension, syncope, vomiting, rash.
- Rare (<1/1000): Priapism (a prolonged and painful erection lasting more than 4 hours; requires immediate medical attention to prevent permanent tissue damage), non-arteritic anterior ischemic optic neuropathy (NAION), sudden hearing loss, seizures.
Drug interaction
The pharmacokinetic profile of Sildalis, metabolized primarily by the CYP3A4 enzyme, makes it susceptible to numerous drug interactions:
- Nitrates: Absolute contraindication due to risk of profound hypotension.
- Alpha-blockers: Concomitant use can potentiate the blood-pressure-lowering effects. Concomitant use is not recommended. If co-administration is necessary, it should be initiated only under close medical supervision with stable alpha-blocker dosing.
- Potent CYP3A4 Inhibitors: Drugs like ketoconazole, itraconazole, ritonavir, and clarithromycin significantly increase plasma concentrations of Sildalis. Concomitant use is contraindicated.
- Other Antihypertensives: Additive hypotensive effects may occur with other blood pressure-lowering medications.
- Grapefruit Juice: Can inhibit CYP3A4 and should be avoided as it may increase drug exposure and the risk of associated side effects.
Missed dose
Sildalis is prescribed for use on an as-needed basis rather than a continuous daily regimen. Therefore, the concept of a “missed dose” does not apply in the traditional sense. The medication should only be taken when planned sexual activity is anticipated. It is not intended for chronic daily dosing. Do not take a double dose to make up for a missed opportunity.
Overdose
In the event of a suspected overdose, which would likely manifest as severe manifestations of the drug’s known vasodilatory effects (e.g., severe headache, profound hypotension, syncope, prolonged priapism), immediate medical attention is critical. Standard supportive measures should be employed, including placing the patient in a supine position with the legs elevated to manage hypotension. Priapism requires immediate urological intervention to irrigate the corpora cavernosa. Dialysis is not expected to be effective due to high protein binding of the active components.
Storage
- Store Sildalis tablets in their original packaging at room temperature (15°C to 30°C or 59°F to 86°F).
- Protect from light and moisture.
- Keep out of reach of children and pets.
- Do not use the medicine after the expiration date printed on the packaging.
Disclaimer
This information is intended for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here. The efficacy and safety of Sildalis have not been established for all patient populations, and its use must be guided by a licensed healthcare professional who is aware of your complete medical history.
Reviews
- “As a urologist with over 20 years of practice, I reserve Sildalis for complex ED cases where single-agent therapy has failed. The dual-action mechanism provides a reliable solution for my patients seeking both rapid onset and extended duration. My clinical experience aligns with the pharmacological promise, showing significant improvement in IIEF scores.” – Dr. Evan R., MD, Urology
- “After trying sildenafil alone with inconsistent results, my specialist recommended Sildalis. The difference was remarkable. The flexibility is its greatest asset—I no longer feel like I’m racing against a clock. It has effectively restored normal function with minimal side effects, just some mild flushing initially.” – Patient, M, 58
- “From a clinical trial perspective, the combination product demonstrates a predictable pharmacokinetic profile. While it expands the therapeutic arsenal, it necessitates rigorous patient selection and education due to the potentiated risk profile. It is a valuable, though niche, option in men’s health.” – Clinical Pharmacologist, Research Institute
- “The convenience of a single tablet that covers both bases is a game-changer for patient compliance. However, it mandates a thorough cardiometabolic workup beforehand. It’s not a first-line option but an excellent step for appropriate, well-informed patients under close supervision.” – Nurse Practitioner, Men’s Health Clinic